Teva (TEVA) Sues Forest Labs (FRX) Over Alzheimer's Disease Drug
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) is said to have filed a lawsuit against Forest Labs (NYSE: FRX) over patent infringement, according to Bloomberg headlines.
The suit, filed in Delaware, is related to Forest's Alzheimer's disease drug Namenda XR
The patent in question is U.S. patent number 6,194,000, which was awarded to Teva in 2001.
Namenda was launched in the U.S. in June 2013.
The suit, filed in Delaware, is related to Forest's Alzheimer's disease drug Namenda XR
The patent in question is U.S. patent number 6,194,000, which was awarded to Teva in 2001.
Namenda was launched in the U.S. in June 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Teva bids $57.5M for BioXcel agitation drug in bankruptcy sale
- Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Create E-mail Alert Related Categories
Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
